

Table 1.21  
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2006<sup>a</sup>  
Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			31-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 31 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 31 Years <sup>d</sup>
All Sites	Both Sexes	4,077,488	4,154,826	4,519,388	10,831,324	11,027,782
	Male	2,080,191	2,108,988	2,284,134	5,056,502	5,116,252
	Female	1,997,297	2,045,838	2,235,254	5,774,822	5,911,530
Oral Cavity & Pharynx	Both Sexes	88,149	100,786	104,275	229,332	251,715
	Male	59,730	67,492	69,596	148,389	161,197
	Female	28,419	33,294	34,679	80,943	90,518
Esophagus	Both Sexes	18,231	21,903	21,915	27,407	32,201
	Male	13,976	16,810	16,810	20,647	24,147
	Female	4,255	5,093	5,105	6,760	8,054
Stomach	Both Sexes	31,763	38,156	38,279	62,024	71,142
	Male	19,112	22,988	23,004	35,526	40,842
	Female	12,651	15,168	15,275	26,498	30,300
Colon & Rectum	Both Sexes	410,878	473,926	481,943	1,063,937	1,184,011
	Male	207,419	239,595	243,087	522,508	578,045
	Female	203,459	234,331	238,856	541,429	605,966
Liver & Intrahepatic Bile Duct	Both Sexes	18,570	20,914	20,914	24,536	27,242
	Male	13,017	14,616	14,616	16,411	18,199
	Female	5,553	6,298	6,298	8,125	9,043
Pancreas	Both Sexes	23,089	27,435	27,446	30,784	35,776
	Male	11,266	13,503	13,514	14,813	17,277
	Female	11,823	13,932	13,932	15,971	18,499
Larynx	Both Sexes	30,174	35,697	35,972	88,041	97,768
	Male	24,109	28,434	28,686	70,364	77,761
	Female	6,065	7,263	7,286	17,677	20,007
Lung & Bronchus	Both Sexes	209,050	260,966	266,149	354,138	426,254
	Male	98,835	124,555	126,720	165,363	199,378
	Female	110,215	136,411	139,429	188,775	226,876
Melanoma of the Skin	Both Sexes	233,089	260,265	269,851	714,792	765,882
	Male	122,409	139,106	145,296	353,155	381,997
	Female	110,680	121,159	124,555	361,637	383,885
Breast	Female	801,058	861,011	905,789	2,442,116	2,589,991
Cervix	Female	39,451	41,186	41,269	192,354	197,813
Corpus & Uterus, NOS	Female	146,768	165,629	165,699	518,293	563,072
Ovary <sup>f</sup>	Female	54,346	63,586	63,631	154,428	173,886

<sup>a</sup> U.S. 2006 cancer prevalence counts are based on 2006 cancer prevalence proportions from the SEER 9 registries and 1/1/2006 U.S. population estimates based on the average of 2005 and 2006 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever

<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 31 years (1975-2005)

<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2001-2005)  
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2001; Melanoma in 2002.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 31-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2006.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 31-year limited duration prevalence. The 2001 breast cancer is counted for the breast 5-year and 31-year limited duration prevalence.

In method (e) the 2001 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2002 melanoma is counted for 5-year limited duration prevalence for melanoma.

<sup>f</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued  
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2006<sup>a</sup>  
 Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			31-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 31 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 31 Years <sup>d</sup>
Prostate	Male	930,125	1,003,839	1,003,911	2,174,982	2,320,295
Testis	Male	39,842	40,565	41,075	172,591	174,841
Urinary Bladder	Both Sexes	188,227	231,571	235,384	508,818	586,875
	Male	140,439	173,578	176,622	376,871	433,882
	Female	47,788	57,993	58,762	131,947	152,993
Kidney & Renal Pelvis	Both Sexes	111,278	134,837	135,889	254,925	295,615
	Male	66,844	81,868	82,613	150,001	175,152
	Female	44,434	52,969	53,276	104,924	120,463
Brain & Nervous System	Both Sexes	39,632	41,635	41,953	108,661	111,711
	Male	21,221	22,407	22,579	58,031	59,668
	Female	18,411	19,228	19,374	50,630	52,043
Thyroid	Both Sexes	120,479	130,868	131,194	367,333	387,569
	Male	26,876	30,552	30,586	81,388	87,358
	Female	93,603	100,316	100,608	285,945	300,211
Hodgkin Lymphoma	Both Sexes	35,015	36,820	36,831	145,147	148,461
	Male	18,420	19,309	19,320	74,925	76,593
	Female	16,595	17,511	17,511	70,222	71,868
Non-Hodgkin Lymphoma	Both Sexes	178,216	206,582	208,073	407,962	452,723
	Male	92,687	108,381	109,127	211,075	233,951
	Female	85,529	98,201	98,946	196,887	218,772
Myeloma	Both Sexes	39,615	45,364	45,401	58,905	66,529
	Male	21,534	24,854	24,878	32,370	36,858
	Female	18,081	20,510	20,523	26,535	29,671
Leukemia	Both Sexes	96,231	108,820	108,981	225,790	245,225
	Male	55,777	63,265	63,346	127,972	139,195
	Female	40,454	45,555	45,635	97,818	106,030
Acute Lymphocytic Leukemia	Both Sexes	15,118	15,404	15,404	55,306	55,720
	Male	8,660	8,708	8,708	30,447	30,533
	Female	6,458	6,696	6,696	24,859	25,187
Childhood (Ages 0-19)	Both Sexes	60,231	60,330	60,634	259,480	259,966
	Male	32,416	32,472	32,581	133,367	133,580
	Female	27,815	27,858	28,053	126,113	126,386
Kaposi Sarcoma	Both Sexes	6,695	7,138	7,138	21,168	22,209
	Male	6,215	6,544	6,544	19,850	20,703
	Female	480	594	594	1,318	1,506
Mesothelioma	Both Sexes	2,774	3,453	3,453	4,194	5,000
	Male	2,022	2,510	2,510	2,603	3,185
	Female	752	943	943	1,591	1,815

<sup>a</sup> U.S. 2006 cancer prevalence counts are based on 2006 cancer prevalence proportions from the SEER 9 registries and 1/1/2006 U.S. population estimates based on the average of 2005 and 2006 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever

<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 31 years (1975-2005)

<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2001-2005)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2001; Melanoma in 2002.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 31-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2006.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 31-year limited duration prevalence. The 2001 breast cancer is counted for the breast 5-year and 31-year limited duration prevalence.

In method (e) the 2001 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2002 melanoma is counted for 5-year limited duration prevalence for melanoma.